MX2015013285A - Use of the acetic acid compound 2-[1-[[(1r)-1-[3-[2-(7-chloroquin olin-2-yl) etenyl] phenyl]-3-[2-(2-hydroxypropan-2-) phenyl] propyl] sulfanylmethyl] cyclopropyl] as alosteric inhibitor of the dengue virus ns2b/ns3 protease. - Google Patents
Use of the acetic acid compound 2-[1-[[(1r)-1-[3-[2-(7-chloroquin olin-2-yl) etenyl] phenyl]-3-[2-(2-hydroxypropan-2-) phenyl] propyl] sulfanylmethyl] cyclopropyl] as alosteric inhibitor of the dengue virus ns2b/ns3 protease.Info
- Publication number
- MX2015013285A MX2015013285A MX2015013285A MX2015013285A MX2015013285A MX 2015013285 A MX2015013285 A MX 2015013285A MX 2015013285 A MX2015013285 A MX 2015013285A MX 2015013285 A MX2015013285 A MX 2015013285A MX 2015013285 A MX2015013285 A MX 2015013285A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- sulfanylmethyl
- hydroxypropan
- cyclopropyl
- propyl
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title abstract 6
- -1 acetic acid compound Chemical class 0.000 title abstract 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title abstract 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 title abstract 3
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 title abstract 3
- 108700005835 Dengue virus nonstructural protein 2B Proteins 0.000 title 1
- 108010000350 dengue virus NS3 protease Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 abstract 3
- 239000004365 Protease Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000725619 Dengue virus Species 0.000 abstract 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 229960005127 montelukast Drugs 0.000 abstract 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 2
- 208000001490 Dengue Diseases 0.000 abstract 1
- 206010012310 Dengue fever Diseases 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108700010756 Viral Polyproteins Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 229940125528 allosteric inhibitor Drugs 0.000 abstract 1
- 208000025729 dengue disease Diseases 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 210000003292 kidney cell Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure is related to a new use of the acetic acid compound 2-[1-[[(1R)-1-[3-[2-(7-chloroquinolin-2-yl) ethenyl] phenyl]-3-[2-(2-hydroxypropan-2-yl) phenyl] propyl] sulfanylmethyl] cyclopropyl] (Montelukast) as an allosteric inhibitor of the the dengue virus protease NS2B / NS3, with the aim of eradicating the reproduction of the dengue virus in infected people by adhesion of the compound to the activation site of the complex forming the NS2B and NS3 proteins, proteases precursors of the dengue viral polyprotein. The compound is effective when the virus has infected human cells, specifically monocytes, hepatocytes, neurons, kidney cells. The compound binds to a conserved site behind the active site, causing the NS2B and NS3 protein complex to lose the protease function. The acetic acid compound 2-[1-[[(1R)-1-[3-[2-(7-chloroquinolin-2-yl) ethenyl] phenyl]-3-[2-(2-hydroxypropan-2-yl) phenyl] propyl] sulfanylmethyl] cyclopropyl] (Montelukast) is characterized by having a m inimal inhibitory dose of 160 ug/ml and a maximum inhibitory dose of 10 mg/ml in humans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2015013285A MX2015013285A (en) | 2015-09-17 | 2015-09-17 | Use of the acetic acid compound 2-[1-[[(1r)-1-[3-[2-(7-chloroquin olin-2-yl) etenyl] phenyl]-3-[2-(2-hydroxypropan-2-) phenyl] propyl] sulfanylmethyl] cyclopropyl] as alosteric inhibitor of the dengue virus ns2b/ns3 protease. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2015013285A MX2015013285A (en) | 2015-09-17 | 2015-09-17 | Use of the acetic acid compound 2-[1-[[(1r)-1-[3-[2-(7-chloroquin olin-2-yl) etenyl] phenyl]-3-[2-(2-hydroxypropan-2-) phenyl] propyl] sulfanylmethyl] cyclopropyl] as alosteric inhibitor of the dengue virus ns2b/ns3 protease. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013285A true MX2015013285A (en) | 2017-03-16 |
Family
ID=58776027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013285A MX2015013285A (en) | 2015-09-17 | 2015-09-17 | Use of the acetic acid compound 2-[1-[[(1r)-1-[3-[2-(7-chloroquin olin-2-yl) etenyl] phenyl]-3-[2-(2-hydroxypropan-2-) phenyl] propyl] sulfanylmethyl] cyclopropyl] as alosteric inhibitor of the dengue virus ns2b/ns3 protease. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX2015013285A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112040954A (en) * | 2018-04-27 | 2020-12-04 | 雷莫内克斯生物制药有限公司 | Pharmaceutical composition for preventing or treating flavivirus infection |
| CN113827599A (en) * | 2021-09-23 | 2021-12-24 | 天津国际生物医药联合研究院 | Potential application of demethylzelaronal in resisting dengue virus infection |
-
2015
- 2015-09-17 MX MX2015013285A patent/MX2015013285A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112040954A (en) * | 2018-04-27 | 2020-12-04 | 雷莫内克斯生物制药有限公司 | Pharmaceutical composition for preventing or treating flavivirus infection |
| CN113827599A (en) * | 2021-09-23 | 2021-12-24 | 天津国际生物医药联合研究院 | Potential application of demethylzelaronal in resisting dengue virus infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591745A1 (en) | 3-PYRIMIDIN-4-IL-OXAZOZOLIDIN-2-ONE AS INHIBITORS MUTANT IDH | |
| EA201391236A1 (en) | NEW CYCLIC DERIVATIVES OF AZABENZIMIDAZOLE, USED AS ANTI-DIABETIC AGENTS | |
| MX2018003206A (en) | Hepatitis b core protein modulators. | |
| EA201690872A2 (en) | ANTI-VIRAL THERAPY | |
| WO2010034670A3 (en) | Host cell kinases as targets for antiviral therapies against hcv infection | |
| EA202090530A1 (en) | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | |
| EA201290575A1 (en) | FLAVIVIRIDAE VIRUS INHIBITORS | |
| EA201590931A1 (en) | HETEROCYCLIC SUBSTITUTED DERIVATIVES 2-AMINO-HINAZOLINE FOR THE TREATMENT OF VIRAL INFECTIONS | |
| NZ604598A (en) | Naphth-2-ylacetic acid derivatives to treat aids | |
| EA201590343A1 (en) | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | |
| RS53209B (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
| EA201590667A1 (en) | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | |
| EA201391468A1 (en) | 1,3-oxazines as BACE1 and / or Bace2 inhibitors | |
| EA201691242A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING AZD9291 | |
| EA202091113A1 (en) | NEW HIGHLY ACTIVE AMINOTHIAZOL SUBSTITUTED INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV) | |
| WO2012103524A3 (en) | Inhibitors of mtor kinasa as anti- viral agents | |
| EA201691402A1 (en) | PHARMACEUTICAL PREPARATION CONTAINING A COMPOUND OF THE PYRIDYLAMINOACIC ACID | |
| AU2015205179A1 (en) | Pharmaceutical composition containing pyridylamino acetic acid compound | |
| WO2012061248A3 (en) | Novel specific hcv ns3 protease inhibitors | |
| MX354676B (en) | Benzofuran compounds for the treatment of hepatitis c virus infections. | |
| EA025948B1 (en) | COMBINATION OF A PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A mTOR INHIBITOR | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| EA201792608A3 (en) | APPLICATION OF P3 BACTERIOPHAG PROTEIN AS AN AGYLINES CONNECTING AMYLOID | |
| MX2015013285A (en) | Use of the acetic acid compound 2-[1-[[(1r)-1-[3-[2-(7-chloroquin olin-2-yl) etenyl] phenyl]-3-[2-(2-hydroxypropan-2-) phenyl] propyl] sulfanylmethyl] cyclopropyl] as alosteric inhibitor of the dengue virus ns2b/ns3 protease. | |
| EA200801614A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING MONTELUKAST |